Alkem Laboratories Ltd vs Glaxosmithkline Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Alkem Laboratories Ltd is ₹ 5405 as of 05 May 15:30 . The P/E Ratio of Alkem Laboratories Ltd changed from 20.9 on March 2021 to 26.9 on March 2025 . This represents a CAGR of 5.18% over 5 yearsThe P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 68.1 on March 2021 to 52.5 on March 2025 . This represents a CAGR of -5.07% over 5 years The Market Cap of Alkem Laboratories Ltd changed from ₹ 33145 crore on March 2021 to ₹ 58347 crore on March 2025 . This represents a CAGR of 11.97% over 5 yearsThe Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 24401 crore on March 2021 to ₹ 48743 crore on March 2025 . This represents a CAGR of 14.84% over 5 years The revenue of Alkem Laboratories Ltd for the Dec '25 is ₹ 3879 crore as compare to the Sep '25 revenue of ₹ 4104 crore. This represent the decline of -5.48% The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 1091 crore as compare to the Sep '25 revenue of ₹ 1016 crore. This represent the growth of 7.4% The ebitda of Alkem Laboratories Ltd for the Dec '25 is ₹ 918.31 crore as compare to the Sep '25 ebitda of ₹ 1024 crore. This represent the decline of -10.36% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 421.44 crore as compare to the Sep '25 ebitda of ₹ 371.94 crore. This represent the growth of 13.31% The net profit of Alkem Laboratories Ltd changed from ₹ 550.24 crore to ₹ 653.53 crore over 7 quarters. This represents a CAGR of 10.33% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 182.33 crore to ₹ 295.62 crore over 7 quarters. This represents a CAGR of 31.80% The Dividend Payout of Alkem Laboratories Ltd changed from 21.28 % on March 2021 to 23.59 % on March 2025 . This represents a CAGR of 2.08% over 5 yearsThe Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 142.13 % on March 2021 to 99.54 % on March 2025 . This represents a CAGR of -6.88% over 5 years .

About Alkem Laboratories Ltd

Headquartered in Mumbai, India, Alkem Laboratories Limited is a leading Indian pharmaceutical company with global operations.
The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.
The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and international markets. Alkem Laboratories Limited was incorporated as a private limited company on August 8, 1973 in Patna and subsequently became a deemed public limited company on October 26, 1988.
Pursuant to Company passing a resolution under section 21 of Companies Act, 1956 and upon issuance of a fresh certificate of incorporation consequent on change of name dated August 21, 2001, the name of the Company was changed to 'Alkem Laboratories Limited' with effect from October 26, 1988.

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

FAQs for the comparison of Alkem Laboratories Ltd and Glaxosmithkline Pharmaceuticals Ltd

Which company has a larger market capitalization, Alkem Laboratories Ltd or Glaxosmithkline Pharmaceuticals Ltd?

Market cap of Alkem Laboratories Ltd is 64,029 Cr while Market cap of Glaxosmithkline Pharmaceuticals Ltd is 39,829 Cr

What are the key factors driving the stock performance of Alkem Laboratories Ltd and Glaxosmithkline Pharmaceuticals Ltd?

The stock performance of Alkem Laboratories Ltd and Glaxosmithkline Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alkem Laboratories Ltd and Glaxosmithkline Pharmaceuticals Ltd?

As of May 5, 2026, the Alkem Laboratories Ltd stock price is INR ₹5355.2. On the other hand, Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2351.1.

How do dividend payouts of Alkem Laboratories Ltd and Glaxosmithkline Pharmaceuticals Ltd compare?

To compare the dividend payouts of Alkem Laboratories Ltd and Glaxosmithkline Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.